Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
Abstract Concurrent chemoradiation therapy (CRT) is the standard of care for patients with unresectable stage II/III lung cancer. However, systemic chemotherapy is required for patients who are ineligible for radical radiation therapy. There is little evidence to date for the safety and efficacy of...
Saved in:
Main Authors: | Taichi Matsubara, Shinkichi Takamori, Takatoshi Fujishita, Ryo Toyozawa, Kensaku Ito, Masafumi Yamaguchi, Takashi Seto, Tatsuro Okamoto |
---|---|
Format: | article |
Language: | EN |
Published: |
Wiley
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/34e9b456402f4b74b9a51df3acabdd4c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adaptive Radiation Therapy in the Treatment of Lung Cancer: An Overview of the Current State of the Field
by: Huzaifa Piperdi, et al.
Published: (2021) -
Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
by: Nathaniel Wiest, et al.
Published: (2021) -
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
by: Anwen Xiong, et al.
Published: (2021) -
Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma
by: Takamori S, et al.
Published: (2020) -
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
by: Barrows SM, et al.
Published: (2019)